HAVANA, June 21 (Reuters) - Cuba said on Monday its three-shot Abdala vaccine against the coronavirus had proved 92.28% effective in last-stage clinical trials.
The announcement came just days after the government said another homegrown vaccine, Soberana 2, had proved 62% effective with just two of its three doses. ...
The announcement came from state-run biopharmaceutical corporation BioCubaFarma, which oversees Finlay, the maker of Soberana 2, and the Center for Genetic Engineering and Biotechnology, the producer of Abdala.
The U.S. government spent more than $18 billion last year funding drugmakers to make a Covid vaccine, an effort that lead to at least five highly effective shots in record time. Now it’s pouring more than $3 billion on a neglected area of research: developing pills to fight the virus early in the course of infection, potentially saving many lives in the years to come.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/P7KP557GE5PJFNCRO2H6LYUGEA.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/NOEFQL22BJOMPOJT5WDNV5ABZ4.jpg)
